Ligand id: 6881

Name: tocilizumab

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: tocilizumab

No information available.
Summary of Clinical Use
Approved as a treatment for rheumatoid arthritis and systemic and polyarticular juvenile idiopathic arthritis.
In May 2017 tocilizumab became the first FDA approved drug for the treatment of adults with giant cell arteritis.
Phase 3 clinical trials for immune conditions including ankylosing spondylitis, hand osteoarthritis, systemic sclerosis and primary Sjögren's syndrome (pSS) are ongoing. Tocilizumab was initally used off-label to manage severe or life-threatening cytokine release syndrome (CRS), which is a serious, and potentially life-threatening side effect of CAR T-cell therapy. In September 2017, the FDA extended tocilizumab approval to include treatment of CAR T-cell therapy-induced CRS. It was approved particularly to manage CRS in patients ≥2 years of age receiving tisagenlecleucel (Kymriah®,CTL019), the first CAR T-cell therapy approved for relapsed and refractory B-cell ALL.
Mechanism Of Action and Pharmacodynamic Effects
Binds to soluble and membrane-bound IL-6 receptors to inhibit IL-6 signalling via these receptors, thereby reducing the effect of the elevated/deregulated circulating IL-6 which is a hallmark of the targeted chronic autoimmume diseases.
External links